About 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor
12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor (GPR31) is a protein
from Homo sapiens identified by UniProt accession
O00270, 319 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor |
| UniProt accession | O00270 |
| Gene | GPR31 |
| Organism | Homo sapiens |
| Length | 319 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (69)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.23
- self reported educational attainment · score 0.10
- breast adenocarcinoma · score 0.10
- Immunodeficiency due to a late component of complements deficiency · score 0.06
- colorectal carcinoma · score 0.06
- isolated agammaglobulinemia · score 0.05
- immunodeficiency 35 · score 0.05
- mannose-binding lectin deficiency · score 0.05
- acne inversa, familial, 3 · score 0.05
- hepatocellular carcinoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00270-F1 | alphafold | PREDICTED | 83.17 | — |
Amino-acid sequence (319 residues)
MPFPNCSAPS TVVATAVGVL LGLECGLGLL GNAVALWTFL FRVRVWKPYA VYLLNLALAD LLLAACLPFL AAFYLSLQAW HLGRVGCWAL HFLLDLSRSV GMAFLAAVAL DRYLRVVHPR LKVNLLSPQA ALGVSGLVWL LMVALTCPGL LISEAAQNST RCHSFYSRAD GSFSIIWQEA LSCLQFVLPF GLIVFCNAGI IRALQKRLRE PEKQPKLQRA QALVTLVVVL FALCFLPCFL ARVLMHIFQN LGSCRALCAV AHTSDVTGSL TYLHSVLNPV VYCFSSPTFR SSYRRVFHTL RGKGQAAEPP DFNPRDSYS
Explore 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets